The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Translational Team Science Award
The FY21 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies must be associated with ongoing or completed clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings. The intent of the TTSA is to utilize information from the clinical trials for research that would then inform the clinic. The TTSA is not intended to support high-throughput screenings, sequencing.
The goal of the TTSA is to bring together a synergistic team of investigators to interrogate clinical problems and queries that may have an impact on patient outcomes.
• Required Pre-Application Deadline: July 29, 2021
• Application Submission Deadline: August 18, 2021
Areas of Interest
To be considered for funding, applications for the FY21 PRCRP Translational Team Science Award must address at least one of the FY21 PRCRP Topic Areas as directed by Congress. Congressional language for the FY21 PRCRP provides funds for research into cancers not addressed in the breast, kidney, lung, pancreatic, prostate, ovarian, rare cancer, and melanoma research programs. Research applications in the areas of breast, kidney, lung, pancreatic, prostate, ovarian, rare cancers, and melanoma are prohibited and will not be accepted. The inclusion of the individual Rare Cancer Research Program shall not prohibit the PRCRP from funding the below mentioned cancers or cancer subtypes that may be rare by definition. The FY21 PRCRP Topic Areas are listed below.
• Bladder cancer • Blood cancers • Brain cancer • New for FY21: Cancers associated with the use of beryllium • Colorectal cancer • New for FY21: Endometrial cancer • Esophageal cancer • New for FY21: Germ cell cancers • Head and neck cancers • Liver cancer • Returning for FY21: Lymphoma • Mesothelioma • Metastatic cancers • Neuroblastoma • Pediatric, adolescent, and young adult cancers1 • Pediatric brain tumors • Stomach cancer • New for FY21: Sarcoma • New for FY21: Thyroid cancer • New for FY21: The link between scleroderma and cancer
For cancers associated with the use of beryllium, proposed research should target mechanistically the process of cancer risk, initiation, and be agnostic to the cancer type.
Metastatic cancer is cancer that has spread from its original location to another place in the body, representing what are known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process.
In addition to addressing at least one of the required FY21 PRCRP Topic Areas, applications for the FY21 PRCRP Translational Team Science Award must also address at least one of the FY21 PRCRP Military Health Focus Areas. It is central to the Vision and Mission of the PRCRP that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, Veterans, and other military beneficiaries (i.e., family members of retirees) (https://cdmrp.army.mil/pubs/video/prc/prcrp_vision_video). The FY21 PRCRP requires all applications to address at least one of the Military Health Focus Areas listed below:
• Environmental exposure risk factors associated with cancer
• Mission Readiness ○ Gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public ○ Gaps in quality of life and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public
The investigator named as the Initiating PI on the application must be at or above the level of Assistant Professor or equivalent. The investigator(s) named as the Partnering PI(s) on the application must be at or above the level of Assistant Professor or equivalent. Postdoctoral fellows are not eligible to be Initiating or Partnering PIs. It is encouraged that at least one of the PIs be a military or VA investigator.
The anticipated direct costs budgeted for the entire period of performance for an FY21 PRCRP TTSA award will not exceed $2.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.